Related Experiment Video

Updated: May 10, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients

Jeffery T Zobell1, Christina Ferdinand, David C Young

  • 1Department or Pharmacy, Intermountain Primary Children's Medical Center, Salt Lake City, Utah; Intermountain Cystic Fibrosis Pediatric Center, Salt Lake City, Utah.

Pediatric Pulmonology
|June 19, 2013
PubMed

Insights

Continuous infusion (CI) of intravenous (IV) meropenem and ticarcillin-clavulanate offers a viable option for treating acute pulmonary exacerbations (APE) in pediatric cystic fibrosis (CF) patients. This method optimizes beta-lactam pharmacodynamics for improved treatment outcomes.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Infectious Diseases

Background:

  • Beta-lactam antibiotics are crucial for treating bacterial infections.
  • Continuous infusion (CI) of certain beta-lactams has been explored in pediatric cystic fibrosis (CF) patients.
  • Optimizing antibiotic pharmacodynamics is key in managing acute pulmonary exacerbations (APE).

Observation:

  • Two pediatric CF patients with APE were treated with intravenous (IV) meropenem and ticarcillin-clavulanate via CI.
  • Previous studies documented CI use for other anti-pseudomonal beta-lactams like aztreonam, cefepime, and ceftazidime.

Findings:

  • Intravenous (IV) meropenem and ticarcillin-clavulanate can be effectively administered via continuous infusion (CI) in pediatric CF patients.
  • This administration route is a feasible alternative for delivering beta-lactam antibiotics.

Implications:

  • Continuous infusion (CI) of beta-lactam antibiotics should be considered to optimize pharmacodynamics (PD) in pediatric CF patients with APE.
  • This approach may enhance treatment efficacy for acute pulmonary exacerbations (APE) in this population.
  • Further research into CI of various beta-lactams is warranted for pediatric CF care.
Keywords:
Inquilinus limosusPseudomonas aeruginosaantibioticsbeta-lactams

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...